Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global animal health and nutrition company with operations across Animal Health, Mineral Nutrition, and Performance Products. This news page aggregates company-issued updates and other coverage related to PAHC stock, helping readers follow developments that Phibro discloses through press releases and regulatory communications.
Phibro’s news flow frequently includes financial results and guidance, such as quarterly and full-year earnings releases and updates to financial outlook for future fiscal years. These announcements often detail net sales by segment, trends in medicated feed additives (MFAs), nutritional specialty products, vaccines, mineral nutrition products, and performance products, as well as commentary on factors like product demand, foreign currency impacts, and operating expenses.
Investors can also expect corporate and strategic announcements, including information about acquisitions or portfolio additions, such as the referenced MFA portfolio acquired from Zoetis, Inc., and enterprise programs like Phibro Forward, which the company describes as focused on efficiency, growth, and cultural engagement. Leadership and governance updates, including planned executive transitions and matters presented at the annual meeting of stockholders, are typically communicated through press releases and accompanying SEC filings.
Product and pipeline-related news is another key category. Phibro has highlighted developments in companion animal oral health, including the licensing agreement with Lighthouse Pharmaceuticals, Inc. for a proprietary compound for canine periodontal care and the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease. Such releases describe product mechanisms, study results, and distribution plans.
In addition, Phibro issues dividend declarations, notices of participation in investor conferences, and details on upcoming webcasts and conference calls to discuss results. Readers interested in PAHC can use this page to monitor these recurring updates and review the company’s own descriptions of its performance, strategy, and product initiatives.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its third quarter financial results on May 4, 2022, after the market closes. A conference call for analysts and investors is scheduled for May 5, 2022, at 9:00 AM Eastern Time. This call will provide insights into the company's performance and future outlook. Interested participants can access the event through Phibro's investor site or by dialing the provided numbers for U.S. and international attendees.
Phibro Animal Health Corporation (NASDAQ:PAHC) is set to participate in the Barclays Global Healthcare Conference on March 15, 2022, at 8:00 AM ET, held in Miami Beach, Florida. CFO Damian Finio will address financial analysts and investors during the event. Attendees can access the live audio presentation through the company's Investor Relations Website. A replay will also be made available afterward. Phibro develops animal health products that aid farmers and veterinarians in producing healthy food sustainably.
Phibro Animal Health Corporation (Nasdaq:PAHC) reported strong financial results for its second quarter ending December 31, 2021, highlighting net sales of $233 million, a 13% increase from the previous year. Net income rose to $17 million, up 36%, with diluted EPS increasing to $0.43, a 34% rise. The company also revised its full-year net sales guidance upward to $890-$920 million. Key revenue drivers included improved demand in Animal Health and Mineral Nutrition segments, despite challenges from rising costs and supply chain issues. Adjusted EBITDA was reported at $29 million.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ: PAHC) declared a quarterly cash dividend of
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the BofA Securities 2022 Virtual Animal Health Summit on February 24, 2022, at 12:40 PM ET. CFO Damian Finio and EVP Daniel Bendheim will present to financial analysts and investors. The session will be available live on the company's Investor Relations Website, with a replay archived afterward. Phibro focuses on providing a wide range of animal health and mineral nutrition products, supporting sustainable food production.
Phibro Animal Health Corporation (NASDAQ: PAHC) announced that the FDA will hold a public hearing on March 10, 2022, regarding its product Mecadox® (carbadox). This antibiotic has been used in the U.S. for 50 years to control bacterial diseases in swine. The FDA seeks data on the product's safety, following past concerns about carcinogenic residues. Phibro has been proactively providing research to confirm the product's safety, stating that it will defend its continued market availability. They anticipate the hearing will support the safe use of Mecadox.
Phibro Animal Health Corporation (NASDAQ:PAHC) is set to announce its second quarter financial results on February 9, 2022, after market close. A conference call and webcast will follow on February 10, 2022, at 9:00 AM ET. Interested parties can join via the company's investor relations website or by calling provided numbers. Phibro develops and supplies a range of animal health products, promoting sustainable livestock management and food production. For more details, visit www.pahc.com.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced its participation in the 4th Annual Evercore ISI Virtual Conference on December 1, 2021, at 8:00 AM ET. Chief Financial Officer Damian Finio and Executive Vice President Daniel Bendheim will present to financial analysts and investors. Participants can access the live audio presentation on the Phibro Investor Relations Website, and a replay will be archived for later listening. Phibro is a global developer and supplier of animal health and mineral nutrition products aimed at supporting sustainable food production.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q1 financial results for the period ending September 30, 2021. Net sales increased by 10% to $215 million, while net income dropped 47% to $7 million. Diluted EPS fell by 47% to $0.16. The company raised its fiscal year net sales guidance to $860-$890 million, citing strong product demand, especially in nutritional specialties and vaccines, despite challenges from increased costs. Gross profit margins decreased to 30.1%. The outlook includes further price adjustments to offset rising freight costs.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
